Let's catch up on the latest news from the stock market. From significant investments to major deals, order wins, appointments and acquisitions, here’s a quick look at which stocks will be in focus in today's trade:
Stocks to Watch
The company's overseas subsidiary, Health City Cayman Islands (HCCI), has entered into a Joint Venture Agreement with 2070 Health Inc., W Health Ventures GP LLC, and Everhope Oncology. The joint venture aims to establish and operate a network of healthcare centers in India, specifically for the treatment of cancer patients, with a focus on chemotherapy services.
The company has signed a Power Purchase Agreement and a Shareholders Agreement with Fourth Partner Solar Power (a special purpose vehicle formed by Fourth Partner Energy) to source solar power from the said SPV for 25 years from the commencement of commercial operations.
The company's subsidiary, HTL, has received a contract worth Rs 44.36 crore from the Indian Army for the supply of tactical optical fiber cable assemblies.
The company has received a work order worth Rs 28.29 crore from Northern Railway. The order involves indoor and outdoor double distant signaling work. Meanwhile, the board will consider a second interim dividend for FY25 on March 12. Additionally, the company has received another work order worth Rs 47.50 crore from East Central Railway.
The gaming and sports media platform has divested its 94.85% stake in OpenPlay Technologies to Moonshine Technology for Rs 104.33 crore. The transaction will be executed through the issuance of Moonshine’s compulsory convertible preference shares (CCPS) to Nazara and other sellers. OpenPlay Technologies runs the popular rummy platform, Classic Rummy, while Moonshine is the parent company of India’s biggest poker platform, PokerBaazi.
The company has received an offer letter from Maharashtra Industrial Township (MITL), offering 26.39 acres of land in Chhatrapati Sambhaji Nagar, Maharashtra, for Rs 37.60 crore for future expansion.
The company reported consolidated crude steel production for February 2025 at 24.07 lakh tonnes, growing 12% over 21.50 lakh tonnes in the same month last year. Capacity utilization at Indian operations stood at 93.5% for February.
The United States Food and Drug Administration (USFDA) conducted an inspection at Unit-1 of the company's subsidiary, Shilpa Pharma Lifesciences, at Raichur from March 3-7, 2025. Post-inspection, the company received one observation in Form 483, which is procedural in nature.
The company's subsidiary, Tata Power Renewable Energy, has signed a Memorandum of Understanding (MoU) with the Government of Andhra Pradesh to develop up to 7,000 MW of renewable energy projects, including solar, wind, and hybrid projects with or without storage solutions. The estimated investment in these projects stands at up to Rs 49,000 crore.
The board has approved an interim dividend of Rs 12.50 per equity share for FY25 and the proposal for divestment of a 100% equity stake in the company's wholly owned subsidiary, GR Galgalia Bahadurganj Highway (GGBHPL).
The company's subsidiary, Biocon Biologics, announced the successful results of a pivotal Phase 3 study comparing Yesintek (Biocon Biologics’ biosimilar to Ustekinumab) with the reference product Stelara (Ustekinumab) in adult patients with moderate to severe chronic plaque psoriasis (PsO).
Oil and Natural Gas Corporation
The company's subsidiary, ONGC Petro Additions (OPaL), has received a letter from the Development Commissioner, Dahej Special Economic Zone, granting final exit to OPaL from the Dahej Special Economic Zone. Accordingly, OPaL shall operate as a domestic tariff area (DTA) unit with effect from March 8. Further, this exit from SEZ will improve OPaL's competitiveness for supplies made to the DTA.
Container Corporation of India
CONCOR has signed a Memorandum of Understanding (MoU) with The Energy and Resources Institute (TERI) for setting up a Centre of Excellence (COE) for green and sustainable logistics at TERI.
The company has acquired an additional 10% stake in its subsidiary, Delhi International Airport (DIAL), from Fraport AG Frankfurt Airport Services Worldwide. Post this acquisition, the company’s shareholding in DIAL has increased from 64% to 74%.
The board has approved the allotment of 36.42 lakh equity shares at an issue price of Rs 1,400 per rights equity share to eligible equity shareholders or applicants.
After approval from the Republic of the Philippines Securities and Exchange Commission, the company's step-down subsidiary, Diversify Intelligent Staffing Solutions Inc., merged with another step-down subsidiary, Diversify ISS BGC Inc. With this merger, Diversify Intelligent Staffing Solutions Inc. ceased to exist effective March 7, 2025.
Toll collections in February grew by 14.4% to Rs 528.7 crore, compared to Rs 462.2 crore in the same month last year. Further, the per-day toll revenue for February 2025 increased 18% YoY to Rs 18.9 crore per day, compared to Rs 15.9 crore per day.
The company has received permission from the Central Drugs Standard Control Organisation to import, sell, and distribute Durvalumab solution. Durvalumab is indicated for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC). The approval paves the way for the marketing of Durvalumab solution for infusion 120 mg/2.4 ml and 500 mg/10 ml (Imfinzi) in India.
The company has inked a Memorandum of Understanding (MoU) with the Indian Institute of Technology, Hyderabad, for establishing a Centre of Clean Coal Energy and Net Zero (CLEANZ) at Hyderabad.
The board has approved the sale of the company's fuel stations in Indore and Bengaluru for Rs 7.5 crore.
The board members will be meeting on March 17 to consider the declaration of an interim dividend for FY25.
The company's production in February 2025 grew by 10.4% year-on-year to 81,302 units, while sales increased by 13% to 80,641 units, and export sales jumped 99% to 3,061 units during the same period.
Bharat Heavy Electricals (BHEL)
The High Court of Delhi has upheld an interim award in favour of BHEL amounting to Rs 115 crore with interest at 18% per annum, effective 30 days from the date of the award (July 27, 2017), against RattanIndia Power.
The pharma major has launched Rivaroxaban tablets (USP, 2.5 mg) in the United States after final approval of its Abbreviated New Drug Application from the US FDA. The drug is bioequivalent to Xarelto tablets by Janssen Pharmaceuticals and is used to reduce the risk of major cardiovascular events in patients with coronary artery disease and thrombotic vascular events in patients with peripheral artery disease.
The USFDA conducted a scheduled inspection at the company’s bioequivalence facility in Vadodara from March 3-7. The USFDA issued a Form 483 with one procedural observation. The company will provide a comprehensive response within the stipulated period.
Stainless steel sales grew by 110% YoY to 8,552 MT in February 2025, while stainless steel average realizations increased 10% YoY to Rs 1.29 lakh per MT.
The Reserve Bank of India (RBI) has approved re-appointment of Sumant Kathpalia as Managing Director & CEO of IndusInd Bank for one year effective March 24, 2025.
The real estate developer's subsidiary Omaxe World Street has launched New Singapore in Faridabad, with a project value of Rs 600 crore.
The company's subsidiary NIIT (USA) Inc, has invested $1 million in 8% convertible notes of StriVR Labs Inc., USA as a part of its strategic initiatives.
Promoter Shiv Nadar has executed a Gift Deed to transfer a 47% stake in HCL Corp and a 47% shareholding in Vama Delhi to his daughter, Roshni Nadar Malhotra.
Stock Trades Ex-Date for Rights
Vipul Organics
A B Infrabuild
Stock Trades Ex-Date for Spin Off
Kesoram Industries
Stock Trades Ex-Bonus
SBC Exports
Stocks in F&O ban
Hindustan Copper
Manappuram Finance
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
